Skip to content
Select your cancer type
▼
  • ESCC
  • GC/GEJC
  • NSCLC
Indication:
▼
  • 1 L ESCC
  • 1 L GC/GEJC
  • 2 L ESCC
  • Non-Squamous NSCLC
  • Squamous NSCLC

Language

This site is inteded for health care proffesional.

NOW APPROVED NEW INDICATION GC/GEJC

FOR YOUR PATIENTS WITH UPPER GI CANCER BRING MORE LIFE TO THE TABLE

In a Squamous NSCLC phase 3 trial (1)

etapidi Product Profile

Etapidi demonstrated clinical benefit regardless of PD-L1 expression.

Active Ingredients:

Tislelizumab is an Fc-engineered humanized immunoglobulin G4 (IgG4) variant monoclonal antibody produced in recombinant Chinese hamster ovary cells.

Excipients:

Trisodium citrate dihydrate, Citric acid monohydrate, L histidine hydrochloride monohydrate, L-histidine, Trehalose dihydrate, polysorbate-20 (E432), and Water for injections.

DISCOVER THE DATA ACROSS ALL INDICATIONS

Explore the 1L ESCC efficacy result
Explore the 1L GC/GEJC efficacy result
Explore the 2L ESCC efficacy result
Explore the 1L Non-squamous NSCLC efficacy result
Explore the 1L Squamous NSCLC efficacy result
Explore the 2L NSCLC efficacy result

1L, first line; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEJC, gastroesophageal junction cancer; GI, gastrointestinal; Squamous NSCLC, Squamous cell non-small cell lung cancer;Non-Squamous NSCLC, Non-Squamous cell non-small cell lung cancer; OS, overall survival.